Insider Selling: Momenta Pharmaceuticals, Inc. (MNTA) President Sells $62,028.12 in Stock
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) President Craig A. Wheeler sold 4,116 shares of the stock in a transaction that occurred on Monday, August 21st. The shares were sold at an average price of $15.07, for a total value of $62,028.12. Following the sale, the president now owns 269,231 shares of the company’s stock, valued at approximately $4,057,311.17. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Craig A. Wheeler also recently made the following trade(s):
- On Thursday, August 10th, Craig A. Wheeler sold 16,953 shares of Momenta Pharmaceuticals stock. The shares were sold at an average price of $16.94, for a total value of $287,183.82.
Shares of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) traded down 0.94% during mid-day trading on Friday, hitting $15.80. The company’s stock had a trading volume of 341,086 shares. The company’s market cap is $1.17 billion. The company has a 50-day moving average of $16.37 and a 200 day moving average of $15.60. Momenta Pharmaceuticals, Inc. has a 1-year low of $10.75 and a 1-year high of $19.90.
Momenta Pharmaceuticals (NASDAQ:MNTA) last released its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($0.50) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.50). Momenta Pharmaceuticals had a negative net margin of 39.35% and a negative return on equity of 12.28%. The business had revenue of $23.57 million during the quarter, compared to analyst estimates of $24.64 million. During the same period in the previous year, the business earned ($0.31) EPS. Momenta Pharmaceuticals’s revenue was down 10.8% compared to the same quarter last year. On average, analysts expect that Momenta Pharmaceuticals, Inc. will post ($1.09) EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Daily Political and is owned by of Daily Political. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright law. The legal version of this piece of content can be accessed at https://www.dailypolitical.com/2017/08/26/insider-selling-momenta-pharmaceuticals-inc-mnta-president-sells-62028-12-in-stock.html.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Ameritas Investment Partners Inc. raised its position in Momenta Pharmaceuticals by 14.9% in the second quarter. Ameritas Investment Partners Inc. now owns 6,446 shares of the biotechnology company’s stock worth $109,000 after buying an additional 834 shares in the last quarter. Tortoise Investment Management LLC acquired a new position in Momenta Pharmaceuticals during the second quarter worth $114,000. Pinebridge Investments L.P. raised its position in Momenta Pharmaceuticals by 4.3% in the second quarter. Pinebridge Investments L.P. now owns 8,798 shares of the biotechnology company’s stock worth $149,000 after buying an additional 363 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in Momenta Pharmaceuticals during the first quarter worth $158,000. Finally, BNP Paribas Arbitrage SA raised its position in Momenta Pharmaceuticals by 13.3% in the first quarter. BNP Paribas Arbitrage SA now owns 13,393 shares of the biotechnology company’s stock worth $179,000 after buying an additional 1,570 shares in the last quarter. Institutional investors and hedge funds own 87.15% of the company’s stock.
Several brokerages recently weighed in on MNTA. BidaskClub downgraded Momenta Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday. Zacks Investment Research downgraded Momenta Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, August 4th. Maxim Group set a $6.00 target price on Momenta Pharmaceuticals and gave the company a “sell” rating in a research note on Thursday, August 3rd. Stifel Nicolaus restated a “buy” rating and set a $26.00 target price on shares of Momenta Pharmaceuticals in a research note on Thursday, August 3rd. Finally, Barclays PLC downgraded Momenta Pharmaceuticals from an “overweight” rating to an “equal weight” rating and decreased their target price for the company from $20.00 to $17.00 in a research note on Monday, May 22nd. Three equities research analysts have rated the stock with a sell rating, four have given a hold rating and two have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $16.63.
Momenta Pharmaceuticals Company Profile
Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).
Receive News & Ratings for Momenta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.